A new study in the Journal of Hepatology adds NAFLD to the list of diseases associated with a Western diet that includes relatively high consumption of red and processed meat
Long-term proton pump inhibitor (PPI) use does not increase the risk of hip fracture among persons with Alzheimer’s disease, according to a new study from the University of Eastern Finland. The risk of hip fracture was slightly increased for PPI use of less than one year, but not for long-term or cumulative use during a follow-up period of 10 years. In addition, there were no significant differences between PPI drug substances and the associated risk of hip fracture. The findings were published in Alimentary Pharmacology & Therapeutics.
Younger patients face highest risks
Proton pump inhibitors (PPIs)—medications commonly used to treat heartburn, acid reflux, and ulcers—have been linked with potentially serious side effects including a possible increased risk of bone fractures. In a new Alimentary Pharmacology & Therapeutics study, however, patients with Barrett’s eosophagus—a long-term complication of acid reflux— who took high doses of PPIs for prolonged periods were no more likely to have bone fractures or evidence of bone thinning (osteopenia or osteoporosis) than people in the general population.
Statins used for the treatment of high cholesterol may have other beneficial effects, but there has been reluctance to prescribe them to patients with liver disease because of concerns that they may cause abnormal liver enzyme levels in the blood. In a new Alimentary Pharmacology & Therapeutics analysis of data from the Danish National Patient Registry, patients with cirrhosis of the liver due to alcohol had a 43% lower risk of dying prematurely than patients not on statins.
The intestinal barrier of patients with the gastrointestinal disease IBS allows bacteria to pass more freely than in healthy people, according to a study led by researchers at Linköping University in Sweden. The study, published in the scientific journal Gastroenterology, is the first to investigate IBS using living bacteria.